Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
79 hedge funds and large institutions have $546M invested in Crinetics Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 8 reducing their positions, and 4 closing their positions.
575% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 4
413% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 8
80% more capital invested
Capital invested by funds: $304M → $546M (+$242M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
41% more funds holding
Funds holding: 56 → 79 (+23)
11.58% more ownership
Funds ownership: 84.17% → 95.74% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$34.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.4M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$18.3M |
| 4 |
PA
Perceptive Advisors
New York
|
+$18.3M |
| 5 |
BlackRock
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$17.1M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$8.52M |
| 3 |
Janus Henderson Group
London,
|
-$7.23M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$2.06M |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$782K |
CRNX Hedge Fund Activity: Q2 2020 in Review
79 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2020, worth a combined $546M — up 80% from $304M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CRNX positions and 4 closed out — a net gain of 23 holders — while 41 added to existing stakes and 8 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $34.6M. The largest seller was Vivo Capital, cutting an estimated $17.1M.
- 79 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2020, up from 56 in Q1 2020.
- Funds reported $546M of Crinetics Pharmaceuticals stock for Q2 2020, up 80% quarter-over-quarter.
- 27 funds opened new Crinetics Pharmaceuticals positions in Q2 2020 and 4 closed out, a net change of +23 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2020 was Versant Venture Management, an estimated $34.6M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2020 was Vivo Capital, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2020.